trending Market Intelligence /marketintelligence/en/news-insights/trending/gxlddihnv1tnsdatxhtkcg2 content esgSubNav
In This List

Lixte Biotechnology names 2 directors

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Lixte Biotechnology names 2 directors

Lixte Biotechnology Holdings Inc. appointed Yun Yen and Winson Ho to its board.

Yen is president emeritus of Taipei Medical University and chair professor of the doctorate program for cancer biology and drug discovery.

Ho is a pediatric neurosurgery fellow at the University of Utah School of Medicine. He previously served as a research fellow at a division of the National Institutes of Health, and conducted research on Lixte's lead clinical compound.

New York-based Lixte Biotechnology develops treatments for cancer and nonmalignant diseases.